Pharma

EU regulation warding off life science investment – IDA chief

The rules are the first major overhaul of the EU’s medicines regulations in 20 years, which aim to make access to medicines more secure and affordable

Michael Lohan, IDA chief executive, said that Europe was becoming ‘too burdensome’ from a regulatory and approval perspective, which could impact innovation. Picture: Maxwells Dublin